JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy

被引:33
作者
Delbue, Serena [2 ]
Elia, Francesca [2 ]
Carloni, Camilla [1 ]
Tavazzi, Eleonora [3 ]
Marchioni, Enrico [3 ]
Carluccio, Silvia [1 ]
Signorini, Lucia [1 ]
Novati, Stefano [4 ]
Maserati, Renato [4 ]
Ferrante, Pasquale [1 ,5 ]
机构
[1] Univ Milan, Dept Publ Hlth Microbiol Virol, I-20133 Milan, MI, Italy
[2] Hlth Sci Fdn, Fdn Ettore Sansavini, Lugo, Ravenna, Italy
[3] IRCCS Natl Neurol Inst C Mondino Fdn, Dept Gen Neurol, Pavia, Italy
[4] IRCCS Policlin San Matteo, Dept Infect Dis, Pavia, Italy
[5] Ist Clin Citta Studi, Milan, Italy
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; INCREASED FREQUENCY; POLYOMAVIRUS; REPLICATION; SEQUENCES; PROMOTER; BRAIN; EXPRESSION; GENOTYPES;
D O I
10.1002/jcp.24051
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Progressive multifocal leukoencephalopathy (PML) is a severe disease of the central nervous system (CNS), caused by infection with the Polyomavirus JC virus (JCV). Because there are no known treatments or prognostic factors, we performed a long-term study focusing mainly on cerebrospinal fluid (CSF) samples from PML patients to describe the virological features akin to the different forms of the disease. Twenty-eight PML patients were enrolled: 10 HIV-1+ patients with classical PML (CPML), 9 HIV-1+ patients with slowly progressing or stable neurological symptoms (benign PML), 3 HIV-1+ asymptomatic patients, and 6 HIV-1-negative patients. CSF, urine, and blood samples were collected at the enrollment (baseline) and every 6 months afterwards when possible. The JCV DNA and HIV-1 RNA loads were determined, and the JCV strains were characterized. At baseline, the mean CSF JCV load was log?6.0 +/- 1.2?copies/ml for CPML patients, log?4.0 +/- 1.0 copies/ml for benign PML patients, log?4.2 +/- 0.5 copies/ml for asymptomatic PML patients, and log?5.8 +/- 1.3?copies/ml for HIV-1-negative PML patients (CPML vs. benign: P?<?0.01; CPML vs. asymptomatic: P?<?0.05; HIV-1 negative vs. benign: P?<?0.01). Organization of the JCV transcriptional control region (TCR) showed unusual archetype structures in two long-term survival patients; the NF1 sequence was found most commonly, whereas the Sp1 binding site was the most common for both CPML patients and HIV-1 negative patients. Our results suggest that the JCV load in the CSF and the organization of the TCR should be considered as indicators of PML clinical outcome. J. Cell. Physiol. 227: 35113517, 2012. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:3511 / 3517
页数:7
相关论文
共 38 条
  • [1] Agostini H T, 1998, J Hum Virol, V1, P200
  • [2] JC virus (JCV) genotypes in brain tissue from patients with progressive multifocal leukoencephalopathy (PML) and in urine from controls without PML: Increased frequency of JCV type 2 in PML
    Agostini, HT
    Ryschkewitsch, CF
    Mory, R
    Singer, EJ
    Stoner, GL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (01) : 1 - 8
  • [3] Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals
    Agostini, HT
    Ryschkewitsch, CF
    Stoner, GL
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (01) : 159 - 164
  • [4] HUMAN POLYOMAVIRUS JC PROMOTER ENHANCER REARRANGEMENT PATTERNS FROM PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY BRAIN ARE UNIQUE DERIVATIVES OF A SINGLE ARCHETYPAL STRUCTURE
    AULT, GS
    STONER, GL
    [J]. JOURNAL OF GENERAL VIROLOGY, 1993, 74 : 1499 - 1507
  • [5] Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy
    Berenguer, J
    Miralles, P
    Arrizabalaga, J
    Ribera, E
    Dronda, F
    Baraia-Etxaburu, J
    Domingo, P
    Márquez, M
    Rodriguez-Arrondo, FJ
    Laguna, F
    Rubio, R
    Rodrigo, JL
    Mallolas, J
    de Miguel, V
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) : 1047 - 1052
  • [6] Progressive Multifocal Leukoencephalopathy and Newer Biological Agents
    Berger, Joseph R.
    [J]. DRUG SAFETY, 2010, 33 (11) : 969 - 983
  • [7] Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy
    Berger, JR
    Levy, RM
    Flomenhoft, D
    Dobbs, M
    [J]. ANNALS OF NEUROLOGY, 1998, 44 (03) : 341 - 349
  • [8] Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy
    Bossolasco, S
    Calori, G
    Moretti, F
    Boschini, A
    Bertelli, D
    Mena, M
    Gerevini, S
    Bestetti, A
    Pedale, R
    Sala, S
    Sala, S
    Lazzarin, A
    Cinque, P
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (05) : 738 - 744
  • [9] PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
    BROOKS, BR
    WALKER, DL
    [J]. NEUROLOGIC CLINICS, 1984, 2 (02) : 299 - 313
  • [10] HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
    Clifford, DB
    Yiannoutsos, C
    Glicksman, M
    Simpson, DM
    Singer, EJ
    Piliero, PJ
    Marra, CM
    Francis, GS
    McArthur, JC
    Tyler, KL
    Tselis, AC
    Hyslop, NE
    [J]. NEUROLOGY, 1999, 52 (03) : 623 - 625